newsfilter
← Latest News
GlobeNewswire·

Hemab Therapeutics to Participate in Upcoming Investor Conferences

  • Hemab Therapeutics (Nasdaq: COAG) announced its management team will attend the 2026 Jefferies Global Healthcare Conference fireside chat in London on Tuesday, November 17, 2026, at 5:00 PM GMT.
  • The company will also participate in the 9th Annual Evercore Healthcare Conference fireside chat in Coral Gables, FL, on Tuesday, December 1, 2026, at 3:00 PM ET.
  • Live webcasts & replays of these presentations will be available under the "Events & Presentations" section on the Investors page of hemab.com.
  • Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders, including sutacimig (HMB-001) for Glanzmann thrombasthenia & Factor VII deficiency, HMB-002 for Von Willebrand Disease, & HMB-003 for heavy menstrual bleeding.
  • Media inquiries are directed to Peg Rusconi at Deerfield, while investor inquiries should be sent to Mads Behrndt at Hemab Therapeutics.
Company
Hemab Therapeutics, Inc.
Keywords
Nasdaq:COAG, Hemab Therapeutics, Inc.